Etanercept in a patient with severe psoriasis and latent viral hepatic disease and latent tuberculosis

American Journal of Clinical Dermatology

Volumn 11, Issue SUPPL. 1, 2010, Pages 57-58

  Prestinari, Francesca ^a   Ferguglia, Guido ^a   Laria, Giuseppe ^a  

^a SANT ANNA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; ISONIAZID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; DRUG EFFICACY; HEPATITIS B VIRUS; HUMAN; LATENT TUBERCULOSIS; LATENT VIRUS INFECTION; LIVER DISEASE; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT FAILURE; VITILIGO;

ANTITUBERCULAR AGENTS; HEPATITIS B; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; ISONIAZID; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; VITILIGO;

EID: 77954249324     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/1153429-S0-000000000-00000     Document Type: Article

References (11)

1. Lawlor C, Kirby B. Neuropeptides and psoriasis. G Ital Dermatol Venereol 2007;142:479-88
2. Martin-Ezquerra G, Ferran M, Pjol RM. Update on therapeutic options for psoriasis. G Ital Dermatol Venereol 2007;142:547-66
3. Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007;8:143-55
4. Boehncke WH, Brasie RA, Barker J, et al. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006;20:988-98
5. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72
6. Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620-2
7. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366-71
8. Desai SB, Furst DE. Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol 2006;20:757-90
9. Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-22
10. Ahmed A, Keeffe E. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999;94:249-51
11. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35:421-4